StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)

Close on Nov 17, 2026Market cap $508.30KP/E –Yield –

Lakewood-Amedex Biotherapeutics cash

Cash and short-term investments held at the end of each period.

Lakewood-Amedex Biotherapeutics's cash was $3.32M at Sep 30, 2026. For fiscal 2025 it was $236.40K, down 65.3% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$236.40K-65.3%
FY2024Dec 31, 2024$681.10K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$3.32M+404.8%
Q2 FY2026Jun 30, 2026$4.58M+261.4%
Q1 FY2026Mar 31, 2026$11.71K-97.5%
Q4 FY2025Dec 31, 2025$236.40K-65.3%
Q3 FY2025Sep 30, 2025$658.41K–
Q2 FY2025Jun 30, 2025$1.27M–
Q1 FY2025Mar 31, 2025$477.01K–
Q4 FY2024Dec 31, 2024$681.10K–

More Lakewood-Amedex Biotherapeutics figures

See a number that looks wrong?